ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026
Synaptic density imaging in behavioral variant frontotemporal dementia: A comparison of
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Synaptic vesicle glycoprotein 2A PET imaging in parkinsonian α-synucleinopathies: a systematic review.Journal of neurology · 2026Pooled it
- PET molecular imaging of in vivo brain metabolism, synaptic density and glial reactivity changes after neural stem cell transplantation on a rat model of ischemic stroke.European journal of nuclear medicine and molecular imaging · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
introductionSynapse loss, a key feature of behavioral variant frontotemporal dementia (bvFTD), can now be visualized in vivo using positron emission tomography (PET) that targets synaptic vesicle glycoprotein 2A (SV2A). Comparing this new imaging method with the clinical standard of glucose metabolism using
methodsWe measured synaptic vesicle glycoprotein 2A (SV2A) binding using
resultsSV2A binding was significantly lower in the frontal and temporal cortices, anterior cingulate, and insula in bvFTD patients, with more widespread and pronounced differences than those observed with DISCUSSION: Our findings suggest that, in bvFTD, the degree of lower synaptic density, as measured by SV2A PET, is larger than the degree of hypometabolism as measured by
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.